Haga Hiroaki, Patel Tushar
Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.
J Hepatobiliary Pancreat Sci. 2015 Feb;22(2):114-23. doi: 10.1002/jhbp.156. Epub 2014 Sep 29.
Intrahepatic cholangiocarcinomas (iCCA) are primary intrahepatic malignancies originating from biliary epithelia. While both hepatocellular cancer and iCCA can present as mass lesions within the liver, these cancers are distinct in their morphology, etiology, pathology, natural history and response to therapy. There is a need for accurate and sensitive molecular markers for the diagnosis of iCCA. Recent advances in elucidating molecular and genetic characteristics of iCCA offer the potential of molecular-based diagnosis of iCCA. Specific genetic mutations of IDH1/2, BAP1, p53, and KRAS, FGFR gene fusions and alterations in microRNA have all been described in iCCA. Although there are no accurate serum or biliary biomarkers currently available for diagnosis of iCCA, several potential candidates have been identified. Knowledge of specific genetic or molecular abnormalities offers potential for individualized approaches for the treatment of patients with iCCA in the future.
肝内胆管癌(iCCA)是起源于胆管上皮的原发性肝内恶性肿瘤。虽然肝细胞癌和iCCA都可表现为肝脏内的肿块病变,但这些癌症在形态、病因、病理、自然史和对治疗的反应方面有所不同。需要准确且敏感的分子标志物来诊断iCCA。在阐明iCCA分子和遗传特征方面的最新进展为基于分子的iCCA诊断提供了潜力。IDH1/2、BAP1、p53和KRAS的特定基因突变、FGFR基因融合以及微小RNA的改变在iCCA中均有描述。尽管目前尚无准确的血清或胆汁生物标志物可用于诊断iCCA,但已确定了几种潜在的候选标志物。了解特定的基因或分子异常为未来iCCA患者的个体化治疗方法提供了潜力。